T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife has raised €93M across 1 funding round from 9 investors, most recently a Series B round in Aug 2021. Based in Berlin, Germany; active in Healthtech. Data as of 28 Oct 2026.
Berlin, Germanyt-knife.com ↗
Total raised
€93M
€92,545,852
Funding rounds
1
Investors
9
distinct backers
Active since
2021-08
latest 2021-08
Funding by year
EUR raised per yearT-knife — funding by year — interactive chart.
Data table
| T-knife — funding by year | |
|---|---|
| 2021 | €93M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-02 | Series B | €93M | Andera Partners,CaaS Capital Management,Casdin Capital,Fidelity Management & Research Company LLC,LSP,Qatar Investment Authority+3 more | View deal → |
Investors
9Related news
Similar companies
same sector or country- Delivery Hero€7.1BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Helsing€2.9BGermany · AI
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
Global coverage: FundingData